The recent success of several ongoing clinical trials for RPE65-Leber congenital amaurosis-2 as well as proof-of-concept studies involving mice, dogs, and monkeys have established that AAV-mediated gene replacement is a feasible strategy for treating a wide variety of RPE and photoreceptor-specific disorders. This evidence concerns the gene RPE65 and Leber congenital amaurosis.